Relay Therapeutics Strategy and Business Model

Executive Overview

Relay Therapeutics is a Cambridge, Massachusetts-based clinical-stage biotechnology company founded in 2015. The company focuses on precision medicines discovered by studying protein motion, using its Dynamo platform to combine computational modeling, structural biology, medicinal chemistry, and experimental biology. Relay’s strategic bet is that understanding how proteins shift between conformations can produce small-molecule drugs with better selectivity and tolerability than earlier generations of targeted therapies. As of 2024, its most important disclosed programs were RLY-2608, a mutant-selective phosphoinositide 3-kinase alpha (PI3Kα) inhibitor being developed with Genentech, and RLY-4008, later named lirafugratinib, a selective fibroblast growth factor receptor 2 (FGFR2) inhibitor for FGFR2-altered cancers, especially cholangiocarcinoma. Relay’s physical footprint is concentrated in the United States, anchored by its Cambridge headquarters and research base, while its clinical-development footprint extends internationally through trial sites, contract manufacturers, and partners. Economically, Relay remained pre-commercial as of FY2023: it had no marketed products, and reported revenue was driven by collaboration activity rather than drug sales. The core strategic question is whether Relay can convert differentiated science into registrational data, durable partnerships, and eventually a focused precision-oncology commercial model.

Relay Therapeutics at a Glance

Logo
Common name	Relay Therapeutics
Full legal name	Relay Therapeutics, Inc.
Headquarters	Cambridge, Massachusetts, United States
Ownership	Public company
Ticker	RLAY
Exchange	NASDAQ
Market Cap	$3.77B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2015; Nasdaq IPO in 2020; major Genentech collaboration on the PI3Kα franchise announced in 2023
Industry or industries	Biotechnology; precision oncology; targeted therapeutics
Key products or services	Clinical-stage small-molecule drug candidates, including RLY-2608 and RLY-4008/lirafugratinib; Dynamo drug-discovery platform
Geographic footprint	U.S.-based research and corporate footprint with global clinical-development reach through sites and partners
Business segments as officially reported	One operating and reportable segment
Company website	https://www.relaytx.com/

1. What Is the Strategy of Relay Therapeutics?

Using the Playing to Win framework, Relay Therapeutics’ strategy is best understood as a focused precision-medicine strategy rather than a broad pharmaceutical strategy. In its 2023 Form 10-K, 2024 investor materials, and program updates, Relay consistently describes its aim as translating insights into protein motion into differentiated small-molecule medicines for genetically defined diseases.

1. 1a. What is the winning aspiration of Relay Therapeutics?

   Relay’s winning aspiration is to build a precision-medicine company that can repeatedly create highly selective drugs by understanding protein motion better than conventional discovery approaches do. In practical terms, “winning” means more than generating interesting biology; it means moving internally discovered medicines into clinically meaningful, potentially registrational settings and proving that its platform can produce better therapeutic windows on difficult targets. Relay has not framed its public strategy around a long-range revenue target. Instead, the company’s near- to medium-term aspiration, as reflected in 2024 communications, is to translate lead assets such as RLY-2608 and RLY-4008 into pivotal-value inflection points and thereby validate the platform.

2. 1b. Where does Relay Therapeutics play?

   Relay plays in biomarker-defined disease areas where protein conformation and selectivity appear unusually important. The company’s disclosed near-term focus is precision oncology, especially pathways such as PI3Kα and FGFR2 where earlier drugs have shown efficacy but also meaningful tolerability or selectivity limits. It is not trying to compete across broad primary-care markets, large diversified pharma categories, or many unrelated modalities at once. Geographically, its development ambition is global, but its operational center of gravity is in the United States, with partnering used to broaden reach.

3. 1c. How does Relay Therapeutics plan to win?

   Relay plans to win by producing more selective small-molecule drugs that can improve the balance between efficacy and tolerability in genomically defined patient populations. Its claim to differentiation is not simply target choice; many of its targets are already biologically validated. The proposed edge is the ability to exploit protein motion and conformational states to design compounds that better discriminate between mutant and normal forms, or between closely related kinases. Relay also uses biomarker-driven development and partnerships, most notably the 2023 Genentech collaboration around the PI3Kα franchise, to expand its reach without having to build a full global commercial infrastructure on its own.

4. 1d. What capabilities must Relay Therapeutics have in place?

   To execute this strategy, Relay needs a tight set of capabilities: advanced computational chemistry and molecular simulation; structural biology; medicinal chemistry; translational biology and biomarker development; clinical development in molecularly selected oncology populations; contract manufacturing and Chemistry, Manufacturing, and Controls (CMC) management; and business-development capability for partnerships. Patient-identification capability also matters because the commercial and clinical value of targeted therapies depends on reliable molecular testing and the ability to enroll the right patients quickly.

5. 1e. What management systems does Relay Therapeutics require?

   Relay’s management systems need to support disciplined portfolio decisions, because it is a clinical-stage company with multiple scientific opportunities but finite capital. Inference from its public disclosures suggests a stage-gated governance model built around program milestones, biomarker evidence, safety data, and cash-runway planning. It also requires formal quality and compliance systems for clinical development, cross-functional asset teams to move candidates from discovery into the clinic, and collaboration-governance processes to manage shared programs such as the PI3Kα work with Genentech.

2. What Are the Current Strategic Initiatives of Relay Therapeutics?

As disclosed in 2023 and 2024 company materials, Relay’s current strategic initiatives are concentrated around a small number of value-driving programs and platform priorities.

• Advance the PI3Kα franchise led by RLY-2608.
  Relay has made RLY-2608 the centerpiece of its near-term strategy. The company has been running the ReDiscover clinical program in patients with PIK3CA-mutant solid tumors, with particular focus on hormone receptor-positive, HER2-negative metastatic breast cancer. The strategic goal is to show that mutant selectivity can preserve pathway efficacy while improving tolerability relative to earlier PI3K-pathway drugs.
• Use the Genentech collaboration to broaden development and commercial options.
  In October 2023, Relay announced a major collaboration with Genentech around RLY-2608 and a next-generation PI3Kα program. Strategically, this does three things at once: it provides non-dilutive capital, brings large-company development and commercial capabilities to an important franchise, and reduces the risk that Relay must fund global development alone.
• Refine the development path for RLY-4008 in FGFR2-altered cancers.
  Relay’s work on RLY-4008 has been focused on FGFR2-driven cancers, particularly intrahepatic cholangiocarcinoma. The key strategic issue is not just whether the drug is active, but whether the dosing, duration, and patient-selection approach can create a sufficiently differentiated benefit-risk profile in a field that already has approved FGFR therapies.
• Keep feeding the pipeline from the Dynamo platform.
  Relay consistently positions itself as a platform-and-pipeline company, not a two-asset company. A current initiative is therefore to convert platform capabilities into additional candidates where conformational selectivity may unlock differentiated medicines, while being selective about which programs deserve internal funding.
• Maintain financial flexibility and portfolio discipline.
  For a pre-commercial biotech, capital allocation is strategic. Relay’s 2024 messaging emphasized runway and prioritization, which implies active portfolio management rather than attempting to advance every discovery program in parallel.

3. What Is the Business Model of Relay Therapeutics?

Relay Therapeutics is not yet a conventional product-revenue biopharma company. Its business model currently has two layers: a present-state collaboration model and a future-state specialty oncology model if its lead assets reach approval.

• What customers actually buy.
  Today, the economic product is largely access to Relay’s science, programs, and development rights through collaborations. In the future, if approved, customers would buy targeted oral oncology medicines prescribed for biomarker-defined patient populations.
• Recurring or repeat-driven versus one-time revenue.
  Relay’s current revenue base is mainly collaboration-driven, which tends to be episodic: upfront payments, milestones, and revenue recognition tied to development obligations. Future drug revenue would be more repeat-driven, because targeted oncology therapies are typically prescribed over time until progression, toxicity, or treatment change.
• Revenue model.
  As of FY2023, Relay had no commercial product revenue. Its monetization model was based on collaboration revenue and financing. If successful commercially, the model could evolve into a mix of direct U.S. product sales, ex-U.S. partnering economics, milestones, and royalties or profit-sharing, depending on asset and geography.
• How pricing power works.
  Pricing power in Relay’s future business would not come from consumer brand strength; it would come from clinical differentiation. In precision oncology, price is supported when a drug delivers meaningful efficacy, manageable safety, and a clear place in treatment sequencing for a genetically defined patient group. That said, pricing is still constrained by competition, payer management, and the availability of alternative targeted agents.
• Why the business mix matters.
  The mix between partnered and self-commercialized assets is strategically important. U.S. self-commercialization can create much higher long-term economics, but it requires medical affairs, market access, patient services, and a sales infrastructure. Partnering, by contrast, lowers capital needs and execution risk but also shares the upside.
• What drives gross margin, operating margin, and cash generation.
  For small-molecule oncology drugs, future gross margins could be attractive because manufacturing costs are usually modest relative to price. Today, however, Relay’s operating model is dominated by research and development expense, clinical-trial spending, and general administrative costs, so operating margins are negative by design. Cash generation currently depends more on capital markets and collaboration structures than on product cash flow.

4. What Products and/or Services Does Relay Therapeutics Sell?

Relay does not yet sell an approved commercial product. What it has today is a portfolio of drug candidates and a discovery platform that supports internal programs and collaborations.

• RLY-2608.
  RLY-2608 is Relay’s most strategically important disclosed asset as of 2024. It is a mutant-selective PI3Kα inhibitor in clinical development, with a particular focus on PIK3CA-mutant breast cancer and related solid-tumor settings. The program matters because it addresses a larger commercial opportunity than many rare-oncology assets and has been validated externally by the Genentech collaboration.
• RLY-4008 (lirafugratinib).
  RLY-4008 is a selective FGFR2 inhibitor being developed for FGFR2-altered cancers, especially intrahepatic cholangiocarcinoma. Its importance lies in whether Relay can establish a differentiated efficacy-and-tolerability profile versus other FGFR-pathway therapies.
• Dynamo platform.
  Relay’s Dynamo platform is not sold as stand-alone software. It is an internal discovery engine used to understand protein motion and design more selective small molecules. Strategically, it is the foundation for future pipeline creation and a reason partners may work with Relay.
• Earlier-stage and partnered programs.
  Beyond the two lead clinical assets, Relay has used its platform to build additional discovery and development programs. These may be less visible to the market today, but they matter because the long-term value of the company depends on whether the platform can generate more than one commercially relevant medicine.

At this stage, RLY-2608 appears to carry the greatest strategic and economic weight, while RLY-4008 remains important as a second proof point for the platform.

5. What Are the Key Competitors or Peers of Relay Therapeutics?

Relay’s competitive set depends on which asset is being considered. Some competitors are direct by molecule or pathway, while others are closer peers in business model or discovery approach.

One nuance matters: Genentech is strategically a partner to Relay through the PI3Kα collaboration, even though the broader PI3K-pathway landscape includes assets associated with Roche and its affiliates. For Relay, the collaboration relationship is more important than treating Genentech as a stand-alone peer.

6. What Is the Marketing Strategy of Relay Therapeutics?

Relay’s marketing strategy is currently scientific and stakeholder-focused rather than consumer-oriented. Because the company has no approved products, its most important marketing activities are presentations at major medical meetings, peer-reviewed publications, scientific communication with key opinion leaders, and clear data messaging to investors and potential partners.

In a company like Relay, medical and scientific credibility is more important than brand advertising. The target audience is narrow: oncologists who treat biomarker-selected patients, investigators running trials, pharmaceutical partners, and the financial community that funds clinical development. Relay’s messaging therefore centers on mechanism, selectivity, clinical data, and differentiation from prior pathway inhibitors.

If a lead asset approaches launch, marketing would likely become more account-based and specialty focused. That would mean educating prescribers on patient selection, molecular testing, treatment sequencing, safety management, and reimbursement. In short, marketing is a supporting capability for Relay today, while the core differentiator remains the science and the clinical data.

7. What Are the Key Customer Segments of Relay Therapeutics?

Relay’s customer mix looks different today than it would after a successful launch.

• Current economic customers: pharmaceutical partners.
  At the current stage, the clearest paying counterparties are collaboration partners. The 2023 Genentech agreement is the best example of how Relay monetizes its science before commercialization.
• Future prescribers: oncologists and cancer centers.
  If approved, Relay’s lead assets would be used by oncologists treating biomarker-defined cancers, especially breast cancer and FGFR2-altered gastrointestinal malignancies. Academic cancer centers and large community oncology networks would matter most.
• Payers and reimbursement stakeholders.
  In specialty oncology, economic access matters. Even when physicians are the prescribers, payers influence uptake through formulary placement, utilization management, and reimbursement rules.
• Patients identified through molecular testing.
  Precision medicine depends on testing infrastructure. Relay’s effective addressable customer base is therefore linked to patients who undergo next-generation sequencing or other molecular diagnostics that identify the relevant mutation or fusion.
• Potential future specialty-physician segments outside oncology.
  If Relay advances programs in genetic disease or adjacent areas, the customer set could broaden to rare-disease specialists and specialty centers. As of 2024, however, the company’s visible commercial focus remains oncology.

That means Relay is not broadly diversified by end market. Its future commercial exposure would initially be concentrated in a small number of specialist disease areas.

8. What Is the Sales Model of Relay Therapeutics?

Relay’s current sales model is business-development-driven rather than product-sales-driven. It does not yet operate like a scaled commercial biopharma company with a national field force. Instead, it monetizes value through collaborations, capital raising, and pipeline advancement.

• Today’s go-to-market model.
  Relay “sells” primarily through strategic partnerships, scientific credibility, and asset differentiation. That means executive outreach, alliance management, and scientific negotiation matter more than traditional sales coverage.
• Likely future U.S. model.
  If RLY-2608 or another asset is approved and Relay keeps meaningful U.S. economics, the likely model would be a focused specialty oncology commercial organization. That would include a small sales force calling on high-value accounts, medical science liaisons, patient-support services, reimbursement support, and strong diagnostic education. This future-state model is an inference based on asset type and the norms of precision-oncology commercialization.
• Likely ex-U.S. model.
  Outside the United States, partnering is often the more capital-efficient route for a company at Relay’s scale. The Genentech collaboration reinforces that logic by combining Relay’s discovery strength with broader development and commercial capabilities.
• How channel structure affects growth and pricing.
  A specialty model creates high customer intimacy and strong medical feedback loops, but adoption can be slower and more evidence-dependent than in broad primary-care markets. Pricing and access depend heavily on clinical differentiation and payer acceptance.

9. In What Geographies Does Relay Therapeutics Operate?

Relay’s physical footprint is concentrated in the United States, especially in Cambridge, Massachusetts, where it houses its headquarters, laboratories, and core corporate functions. It does not have the broad global plant and branch-office network of a large pharmaceutical company.

Its operational reach is broader than its physical footprint, however, because clinical development is conducted through a network of U.S. and international trial sites, contract manufacturers, and external service providers. That is typical for a clinical-stage biotech: the company keeps core science and portfolio control in-house while using external networks to execute studies and supply clinical material.

Commercially, Relay’s long-term opportunity is global, but as of 2024 it remained a development-stage company with its most visible activities and investor base centered in the United States. Partnerships are the most likely mechanism for broadening international reach efficiently.

10. Who Are the Owners of Relay Therapeutics?

Relay Therapeutics is a publicly traded company listed on Nasdaq. Its ownership is institutional and venture-backed rather than founder-controlled.

• As of public filings around 2024, Relay did not appear to have a controlling shareholder.
• Large shareholders reported around that period included affiliates of Third Rock Ventures, The Vanguard Group, and BlackRock, alongside specialist healthcare investors.
• Because Relay is public, the exact ownership mix changes over time through proxy filings and Schedule 13G or 13D disclosures.

11. How Is Relay Therapeutics Organized?

Relay reports one operating and reportable segment, which is typical for a clinical-stage biotechnology company. That legal reporting simplicity, however, does not mean the business is organizationally simple.

In practice, Relay appears to be organized around a matrix of platform capabilities and asset teams. Core scientific functions include computational chemistry, structural biology, medicinal chemistry, biology, and translational science. These capabilities feed program teams responsible for advancing specific assets such as RLY-2608 and RLY-4008. Around that core sit clinical development, regulatory, CMC and technical operations, medical, business development, finance, legal, and corporate functions.

This kind of structure fits Relay’s business model. It allows the company to preserve a central discovery engine while pushing a limited number of high-priority assets through the clinic.

12. How Does Relay Therapeutics Operate?

Relay operates like a platform-enabled clinical-stage biotech whose day-to-day value creation comes from reducing scientific and development risk. The company’s workflow is more akin to a series of de-risking loops than to a traditional manufacturing business.

1. Target and mechanism selection.
   Relay starts by identifying disease-driving proteins where conformational dynamics may offer a path to better selectivity or activity.
2. Drug design and optimization.
   The Dynamo platform is used to understand protein motion and support medicinal chemistry decisions intended to improve potency, selectivity, and drug-like properties.
3. Preclinical development.
   The company then runs pharmacology, toxicology, biomarker, and formulation work needed to nominate development candidates and support Investigational New Drug (IND)-enabling packages.
4. Clinical execution.
   Relay moves lead programs into biomarker-driven clinical trials, where dose finding, safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy data determine whether a program merits larger studies or combination expansion.
5. External manufacturing and supply management.
   Like many biotechs, Relay relies heavily on external manufacturing partners for active pharmaceutical ingredient and drug-product supply, while managing quality, timelines, and regulatory requirements internally.
6. Partnership and portfolio management.
   Because a single data package can materially change value, alliance management, investor communication, and internal prioritization are important operating disciplines, not just corporate overhead.

The operational bottlenecks are typical for precision oncology: enrolling enough molecularly eligible patients, finding the right dose and combination regimen, managing adverse events that can limit duration of therapy, and generating data strong enough to support regulatory discussions.

13. What Are the Growth Opportunities for Relay Therapeutics?

Most plausible growth opportunities

• RLY-2608 in breast cancer.
  The largest visible opportunity is successful development of RLY-2608 in PIK3CA-mutant hormone receptor-positive, HER2-negative breast cancer. If Relay can show a meaningfully better efficacy-and-tolerability profile, the market opportunity is materially larger than that of many niche oncology drugs.
• PI3Kα franchise expansion.
  The Genentech collaboration supports growth beyond a single trial. Additional combinations, earlier lines of therapy, and follow-on molecules could extend the franchise if the biology continues to validate.
• RLY-4008 differentiation in FGFR2-altered tumors.
  If Relay can optimize dosing and positioning, RLY-4008 could still create value in FGFR2-driven cancers despite existing competition.
• New candidates from the Dynamo platform.
  A platform-led company grows most durably when one success leads to more. New discovery programs are therefore a real growth lever, especially if they target areas where Relay’s conformational approach is unusually useful.
• Additional partnering.
  Relay can grow through selective partnerships that bring in capital, development scale, or geographic reach without forcing the company to build a full global organization on its own.

Main constraints

• Clinical and regulatory risk remains the biggest constraint, as it does for any development-stage biotech.
• Competition is intense in both PI3K-pathway and FGFR-targeted oncology.
• Precision-oncology markets are limited by testing rates and the size of biomarker-defined populations.
• Capital discipline matters because even well-funded biotechs can overextend if too many programs are advanced simultaneously.

14. What Is the History of Relay Therapeutics?

Relay Therapeutics was founded in 2015 as a Third Rock Ventures-backed biotechnology company built around the idea that protein motion could change how small-molecule drugs are discovered. Its history is more about platform building and clinical progression than about acquisitions or corporate restructurings.

• 2015: Relay was formed to apply insights into protein dynamics to drug discovery, with an initial focus on precision medicines.
• 2015-2019: The company built out the Dynamo platform and advanced early pipeline work.
• 2020: Relay completed its initial public offering and began life as a publicly traded biotech under the ticker RLAY.
• 2021-2023: Lead programs moved through clinical development, bringing the company from platform promise toward asset-specific clinical proof points.
• October 2023: Relay announced a major collaboration with Genentech around RLY-2608 and a next-generation PI3Kα program, one of the most important strategic milestones in its history to date.
• 2024: Relay continued advancing RLY-2608 and RLY-4008, with portfolio focus increasingly centered on where its science could produce the clearest differentiation.

15. What Is the Technology Strategy of Relay Therapeutics?

Relay’s technology strategy is central to the company’s identity. The Dynamo platform is designed to understand protein motion rather than relying only on static representations of molecular targets. In practice, that means combining computational simulation, structural methods, medicinal chemistry, and experimental biology to identify conformational states that can be exploited for drug design.

The key strategic point is that technology at Relay is an internal competitive enabler, not a separate software product. Relay is not trying to sell discovery software; it is using technology to improve hit discovery, lead optimization, and target selection. This matters most on targets where prior drugs have worked biologically but have been limited by selectivity, tolerability, or resistance issues.

Technology is therefore intertwined with corporate strategy. If Relay’s approach produces clinically differentiated molecules, the platform becomes validated and reusable. If it does not, the company would be judged more like a single-asset biotech than a durable discovery engine.

16. What Is the R&D Strategy of Relay Therapeutics?

For Relay, research and development is the business. The company’s R&D strategy is to focus on genetically validated targets where a better-designed small molecule could create a superior therapeutic index or unlock a previously difficult biology.

• Focus on targets with clear human biology.
  Relay does not appear to be pursuing science for its own sake. Its lead programs are in pathways with established disease relevance, which reduces target-validation risk even if molecule risk remains.
• Pursue differentiation through selectivity.
  The company’s R&D effort is built around the idea that conformational design can create meaningfully better drugs, not merely additional drugs in the same class.
• Use biomarker-driven development.
  Patient selection and translational biomarkers are integral to the R&D model. In precision oncology, development efficiency depends heavily on matching the drug to the right genetic context.
• Study combinations early where the treatment paradigm requires it.
  Relay’s work in breast cancer reflects the reality that targeted oncology drugs often need to fit into combination regimens rather than stand alone.
• Stay portfolio-disciplined.
  A platform company can generate more ideas than it can responsibly fund. Relay’s R&D strategy therefore has to include active pruning and prioritization, not just candidate generation.

17. What Is the Finance Strategy of Relay Therapeutics?

Relay’s finance strategy is that of a clinical-stage biotech trying to maximize scientific optionality without losing balance-sheet control. The company is not managed for near-term earnings; it is managed for runway, milestone creation, and the ability to finance the next stage of development from a position of strength.

• Maintain a substantial cash runway.
  In early 2024, management said existing cash, cash equivalents, and investments were expected to fund planned operations into 2027. That guidance matters because it reduces immediate financing pressure and gives the company more control over portfolio timing.
• Use partnerships as a financing tool, not just a scientific tool.
  The October 2023 Genentech agreement added non-dilutive capital and shared development burden around the PI3Kα franchise.
• Concentrate spending on R&D.
  Relay’s cost base is dominated by research, clinical development, and related infrastructure. There is no dividend model and no mature-cash-flow capital allocation question; the main question is how much capital goes to which program and when.
• Keep operating leverage for later.
  As a pre-commercial company, Relay currently has negative operating margins. If a product reaches market, the small-molecule model could support attractive gross margins, but that is a later-stage economics story rather than a present one.

18. How Companies Like Relay Therapeutics Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in more than 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top consulting firms. Companies like Relay Therapeutics use Umbrex when they need the analytical rigor and specialist problem solving associated with top-tier firms, but do not need a full consulting team and its overhead. For a clinical-stage biotechnology company, that is often the right model: targeted support on strategy, operations, commercialization, finance, technology, or AI around specific inflection points.

1. PI3Kα market strategy and scenario planning for RLY-2608, including treatment-sequencing analysis, competitor response scenarios, and launch-readiness options.
2. Commercial opportunity sizing for biomarker-defined breast cancer and FGFR2-altered tumor segments, with clear assumptions on testing rates, line of therapy, and channel economics.
3. Portfolio prioritization and resource allocation across RLY-2608, RLY-4008, and discovery-stage programs to align spending with probability-adjusted value creation.
4. Clinical-development operations improvement to accelerate site activation, enrollment in genomically selected populations, and trial-execution metrics.
5. Companion diagnostic and biomarker strategy covering testing pathways, lab ecosystem mapping, and physician adoption barriers.
6. Global partnering strategy for ex-U.S. rights, alliance governance, and decision support on which assets to partner versus retain.
7. CMC and supply-network strategy for scaling drug substance and drug product supply from clinical development toward potential launch readiness.
8. Medical-affairs and field-model design for a future specialty oncology launch, including key opinion leader segmentation, account coverage, and reimbursement-support design.
9. Competitive intelligence operating model to track PI3K-pathway, FGFR, and adjacent precision-oncology developments and translate them into management decisions.
10. Finance and PMO support for cash-runway scenario analysis, milestone planning, and cross-functional execution during major data readouts or partnership-driven transitions.